Oral News and Research

RSS

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for diabetes drugs, devices and monitoring systems will reach over $55 billion by 2016, tripling in value.

6 Oct 2009

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced positive top-line clinical results for its lead pain drug Ketotransdel®( )in a Phase 3 trial which evaluated the efficacy and safety of the drug in acute soft tissue injuries of the upper and lower extremities.

6 Oct 2009

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

Vantia Therapeutics today announces that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be safe and well tolerated.

6 Oct 2009

NYBC encourages people to organize community blood drives

With the school season underway, New York Blood Center would like to encourage students, teachers and faculty to please organize blood drives at their schools, a process that teaches community service and leadership skills, and offers a learning experience for both students and the surrounding community.

6 Oct 2009

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $694,000 grant supplement as part of the American Recovery and Reinvestment Act (ARRA) of 2009.

6 Oct 2009

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

GlaxoSmithKline today announced that the United States Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously in support of the approval of VOTRIENT(TM) (pazopanib). Specifically, the panel voted that the benefit-to-risk profile is acceptable for patients with advanced renal cell carcinoma (RCC). Pazopanib is an investigational, oral treatment for patients with advanced RCC.

6 Oct 2009

Group Health Research Institute to receive federal stimulus funds from ARRA

Group Health Research Institute, formerly Group Health Center for Health Studies, will receive more than $15 million in federal stimulus funding from ARRA, the American Recovery and Reinvestment Act of 2009.

6 Oct 2009

Forsyth receives research grants from National Institutes of Health stimulus funding

Four Forsyth scientists have received grants from the latest round of National Institutes of Health stimulus funding through the American Recovery and Reinvestment Act (ARRA) of 2009. To date, Forsyth has received 13 ARRA grants totally nearly $6.4 million. The recent round of funding includes three highly competitive 'Challenge Grants'. The NIH received 22,000 submissions in the Challenge Grant competition ― only about 500 were funded.

6 Oct 2009

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.

5 Oct 2009

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Alnara Pharmaceuticals, Inc., a pharmaceutical company developing novel, non-systemic orally-delivered protein therapeutics for the treatment of metabolic diseases, announced today that results from a landmark, international Phase 3 study of the long-term safety and nutritional benefits of liprotamase for the treatment of pancreatic insufficiency in patients with cystic fibrosis (CF) will be presented at the 23rd Annual North American Cystic Fibrosis Conference (NACFC) being held October 15-17, 2009 in Minneapolis, Minnesota.

5 Oct 2009

Preclinical study results of AVL-181 protease inhibitor presented

Avila Therapeutics, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, pan-genotype, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181.

5 Oct 2009

Discus Dental to host 2010 Las Vegas Extravaganza

Discus Dental®, LLC, innovators in dental and oral-hygiene products and the worldwide leader in professional teeth whitening products, today announced the company will be hosting its 2010 Las Vegas Extravaganza, featuring keynote speaker, former NBC news anchor Tom Brokaw.

5 Oct 2009

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Seattle Genetics, Inc. announced today that it has discontinued the SeaGen MARINER clinical trial based on a determination that the trial would be unlikely to meet its primary endpoint of superior complete response rate in the dacetuzumab combination arm as compared to the placebo combination arm.

5 Oct 2009

Oral Cancer Foundation initiates program to donate VELscope screening systems

The Oral Cancer Foundation recently initiated a program of donating VELscope® Oral Cancer Screening Systems to free clinics and others located in, and helping communities with, underserved populations.

5 Oct 2009

Combination of medications and light therapy effective against head and neck cancers

A combination of medications and a particular light therapy is effective at treating certain types of head and neck cancers in subtropical climates.

5 Oct 2009

Publix Pharmacies offers to compound Tamiflu into an oral suspension for no additional charge

In response to the shortage of Tamiflu in liquid form, all 795 Publix Pharmacies will offer to compound Tamiflu into an oral suspension.

3 Oct 2009

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine.

3 Oct 2009

TNF-alpha inhibitor drug class sales to increase up to $1.1 billion in 2018

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in addition to sales of Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma's Remicade, the two emerging TNF-alpha inhibitors Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe Pharma/Janssen's Simponi will drive sales of the TNF-alpha inhibitor drug class to nearly triple by 2018 for the treatment of ulcerative colitis.

3 Oct 2009

Five-year follow-up study reveals the efficacy of OsseoSpeed implant

The five-year follow-up study was made by Dr. Steveling and co-workers at the Department of Oral and Maxillofacial Surgery at the Heidelberg University in Germany. The conclusion is that the OsseoSpeed implant shows very good results also in compromised sites when using an early loading protocol.

3 Oct 2009

Nutra Pharma manufactures first commercial batch of Cobroxin

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first commercial batch of Cobroxin and has successfully released it for final distribution.

3 Oct 2009

Oral News and Research

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Vantia Therapeutics announces the start of Phase II proof-of-concept trials of its VA111913 drug

NYBC encourages people to organize community blood drives

Sequella receives ARRA funds to manufacture SQ109 for treating tuberculosis

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Group Health Research Institute to receive federal stimulus funds from ARRA

Forsyth receives research grants from National Institutes of Health stimulus funding

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Alnara to announce Phase 3 study results of liprotamase for treating cystic fibrosis at the 23rd NACFC

Preclinical study results of AVL-181 protease inhibitor presented

Discus Dental to host 2010 Las Vegas Extravaganza

Seattle Genetics discontinues its SeaGen MARINER clinical trial for large B-cell lymphoma

Oral Cancer Foundation initiates program to donate VELscope screening systems

Combination of medications and light therapy effective against head and neck cancers

Publix Pharmacies offers to compound Tamiflu into an oral suspension for no additional charge

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

TNF-alpha inhibitor drug class sales to increase up to $1.1 billion in 2018

Five-year follow-up study reveals the efficacy of OsseoSpeed implant

Nutra Pharma manufactures first commercial batch of Cobroxin

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News